Helsinn Hlthcare patents expiration
1. Akynzeo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5202333 | HELSINN HLTHCARE | Tricyclic 5-HT3 receptor antagonists |
Apr, 2015
(9 years ago) | |
| US6297375 | HELSINN HLTHCARE | 4-phenyl-pyridine derivatives |
Mar, 2023
(1 year, 1 month ago) | |
| US10676440 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(11 years from now) | |
| US10961195 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(11 years from now) | |
| US10233154 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(11 years from now) | |
| US9951016 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8623826 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(6 years from now) | |
| US9186357 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(6 years from now) | |
| US9943515 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(6 years from now) | |
| US11559523 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(6 years from now) | |
| US8951969 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(6 years from now) | |
| US10828297 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Dec, 2030
(6 years from now) | |
| US9271975 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Sep, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient
NCE-1 date: 10 October, 2018
Market Authorisation Date: 10 October, 2014
Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limite...
Dosage: CAPSULE;ORAL
AKYNZEO family patents
2. Akynzeo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9403772 | HELSINN HLTHCARE | 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator |
May, 2032
(8 years from now) | |
| US9908907 | HELSINN HLTHCARE | Substituted piperaziniums for the treatment of emesis |
May, 2032
(8 years from now) | |
| US10717721 | HELSINN HLTHCARE | Substituted piperaziniums for the treatment of emesis |
May, 2032
(8 years from now) | |
| US11312698 | HELSINN HLTHCARE | Fosnetupitant chloride hydrochloride having improved stability |
May, 2032
(8 years from now) | |
| US8426450 | HELSINN HLTHCARE | Substituted 4-phenyl pyridines having anti-emetic effect |
May, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186357 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(6 years from now) | |
| US10828297 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Dec, 2030
(6 years from now) | |
| US8895586 | HELSINN HLTHCARE | Methods of treating emesis |
May, 2032
(8 years from now) | |
| US10208073 | HELSINN HLTHCARE | Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator |
May, 2032
(8 years from now) | |
| US11529362 | HELSINN HLTHCARE | Physiologically balanced injectable formulations of fosnetupitant |
Jun, 2037
(13 years from now) | |
| US10624911 | HELSINN HLTHCARE | Physiologically balanced injectable formulations of fosnetupitant |
Jun, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 19, 2023 |
NCE-1 date: 19 April, 2022
Market Authorisation Date: 19 April, 2018
Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
AKYNZEO family patents
3. Aloxi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5202333 | HELSINN HLTHCARE | Tricyclic 5-HT3 receptor antagonists |
Apr, 2015
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5202333 (Pediatric) | HELSINN HLTHCARE | Tricyclic 5-HT3 receptor antagonists |
Oct, 2015
(8 years ago) | |
| US9066980 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(2 months ago) | |
| US9457020 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(2 months ago) | |
| US9173942 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(2 months ago) | |
| US8518981 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(2 months ago) | |
| US7947724 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(2 months ago) | |
| US7947725 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(2 months ago) | |
| US8598219 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(2 months ago) | |
| US8598218 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(2 months ago) | |
| US9125905 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(2 months ago) | |
| US8729094 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(2 months ago) | |
| US7960424 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(2 months ago) | |
| US9439854 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(2 months ago) | |
| US9457021 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(2 months ago) | |
|
US9173942 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(3 months from now) | |
|
US8598219 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(3 months from now) | |
|
US7947724 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(3 months from now) | |
|
US7947725 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(3 months from now) | |
|
US7960424 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(3 months from now) | |
|
US8518981 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(3 months from now) | |
|
US8598218 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(3 months from now) | |
|
US9125905 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(3 months from now) | |
|
US9439854 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(3 months from now) | |
|
US9457021 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(3 months from now) | |
|
US9457020 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(3 months from now) | |
|
US9066980 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(3 months from now) | |
|
US8729094 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-684) | May 27, 2017 |
| M(M-136) | May 27, 2017 |
| Pediatric Exclusivity(PED) | Nov 27, 2017 |
Drugs and Companies using PALONOSETRON HYDROCHLORIDE ingredient
Market Authorisation Date: 29 February, 2008
Treatment: Prevention of chemotherapy-induced nausea and vomiting
Dosage: INJECTABLE;INTRAVENOUS; CAPSULE;ORAL
ALOXI family patents
4. Truseltiq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9067896 | HELSINN HLTHCARE | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof |
Aug, 2028
(4 years from now) | |
| US8552002 | HELSINN HLTHCARE | Compounds and compositions as protein kinase inhibitors |
Aug, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10278969 | HELSINN HLTHCARE | Pharmaceutical dosage forms |
Dec, 2034
(10 years from now) | |
| US11160804 | HELSINN HLTHCARE | Pharmaceutical dosage forms |
Dec, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
| Orphan Drug Exclusivity(ODE-353) | May 28, 2028 |
Drugs and Companies using INFIGRATINIB PHOSPHATE ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: NA
Dosage: CAPSULE;ORAL
TRUSELTIQ family patents